Product Program year 2024 Source: CMS Open Payments

Farydak

Drug Hematology

NDC 0078-0650-06

Open in the dashboard

General payments

$44,782

4 payments

Research payments

$8,811,999

39 payments

Through program year 2024, $44,782 in general payments and $8,811,999 in research payments were reported against Farydak (Hematology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows

General

’19 ’20 ’21 ’22 ’23 ’24

Peak $45K

Research

’19 ’20 ’21 ’22 ’23 ’24

Peak $8.1M

Year	Kind	Amount	Payments
2024	Research	$1,601	1
2023	Research	$20,803	1
2021	Research	$3,850	1
2020	General	$44,782	4
2020	Research	$676,811	10
2019	Research	$8,108,934	26

Breakdown

Who paid General payments · program year 2020

Novartis Pharmaceuticals Corporation $44,782 4 payments

Top recipients General payments · program year 2020

Kenneth Shain Medical Oncology · Tampa, FL $25,054 56% · 1 payment
Peter Voorhees Hematology · Charlotte, NC $15,228 34% · 2 payments
Sagar Lonial Hematology · Atlanta, GA $4,500 10% · 1 payment

Each share is of general payments naming this product in 2020.

Specialties paid General payments · program year 2020

Medical Oncology Internal Medicine $25,054 56% · 1 practitioner
Hematology Internal Medicine $19,728 44% · 2 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2020

Florida $25,054 56% · 1 recipient
North Carolina $15,228 34% · 1 recipient
Georgia $4,500 10% · 1 recipient

Each share is of general payments naming this product in 2020 where a state was reported.

Records

4 general · 39 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.